首页> 美国卫生研究院文献>Cell Transplantation >Ganoderma lucidum Polysaccharide Enzymatic Hydrolysate Suppresses the Growth of Human Colon Cancer Cells via Inducing Apoptosis
【2h】

Ganoderma lucidum Polysaccharide Enzymatic Hydrolysate Suppresses the Growth of Human Colon Cancer Cells via Inducing Apoptosis

机译:Ganoderma lucidum多糖酶水解产物通过诱导细胞凋亡抑制人结肠癌细胞的生长

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Ganoderma lucidum is a popular traditional Chinese medicine used in China to improve health. Previous researches have revealed that the polysaccharide from G. lucidum could exert diversity activities, including immunomodulation, antioxidant, and antitumor effects. However, the effect of enzymatically hydrolyzed G. lucidum polysaccharide (EGLP) in colorectal cancer (CRC) progression remains unknown. The present research aimed to investigate the antitumor mechanism of EGLP in human colon cancer cells. For this purpose, the cytotoxic effects of EGLP were measured by the (3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di-phenytetrazoliumromide (MTT) method. The apoptosis was evoked upon EGLP treatment, which was assayed using flow cytometry. The results indicated that EGLP may induce apoptosis in human colon cancer cell (HCT-116) cells via the upregulation of BCL-2 associated X protein (Bax), phospho-extracellular regulated protein kinases (P-ERK), and cleaved caspase-3 expression and downregulation of B-cell lymphoma-2 (Bcl-2), phospho-serine/threonine kinase 1 (p-Akt1), and cyclo-oxygen-ase (COX-2) expression. The obtained findings indicated EGLP as a new therapeutic agent in fighting CRC.
机译:Ganoderma lucidum是一种在中国使用的受欢迎的中药,以改善健康。以前的研究表明,来自G. lucidum的多糖可以发挥多样性活性,包括免疫调节,抗氧化和抗肿瘤作用。然而,酶促水解的G. lucidum多糖(EGLP)在结肠直肠癌(CRC)进展中的作用仍然未知。本研究旨在研究EGLP在人结肠癌细胞中的抗肿瘤机制。为此目的,通过(3-(4,5) - 二甲基噻唑(-Z-Y1)-3,5-二苯基甲腈(MTT)法测量EGLP的细胞毒性效应。诱导凋亡在EGLP处理时诱发细胞凋亡,使用流式细胞术进行测定。结果表明,EGLP可以通过UpRogutule通过Bcl-2相关的X蛋白(BAX),磷酸磷细胞外调节蛋白激酶(P-ERK)诱导人结肠癌细胞(HCT-116)细胞中的凋亡(P-ERK )和切割的Caspase-3表达和B细胞淋巴瘤-2(Bcl-2),磷酸丝/苏氨酸激酶1(P-AKT1)和环氧-ASE(COX-2)表达的表达和下调。该获得的结果表明EGLP作为战斗CRC的新治疗剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号